Tag Archives: 2014

#437261 How AI Will Make Drug Discovery ...

If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?

Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.

But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.

Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.

GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.

But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.

He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.

Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”

The results have turned what was once a decade-long war into a month-long skirmish.

In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.

Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.

They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.

Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.

Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.

But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.

Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.

On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.

Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.

One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.

Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.

Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.

Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.

Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”

How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: andreas160578 from Pixabay Continue reading

Posted in Human Robots

#437258 This Startup Is 3D Printing Custom ...

Around 1.9 million people in the US are currently living with limb loss. The trauma of losing a limb is just the beginning of what amputees have to face, with the sky-high cost of prosthetics making their circumstance that much more challenging.

Prosthetics can run over $50,000 for a complex limb (like an arm or a leg) and aren’t always covered by insurance. As if shelling out that sum one time wasn’t costly enough, kids’ prosthetics need to be replaced as they outgrow them, meaning the total expense can reach hundreds of thousands of dollars.

A startup called Unlimited Tomorrow is trying to change this, and using cutting-edge technology to do so. Based in Rhinebeck, New York, a town about two hours north of New York City, the company was founded by 23-year-old Easton LaChappelle. He’d been teaching himself the basics of robotics and building prosthetics since grade school (his 8th grade science fair project was a robotic arm) and launched his company in 2014.

After six years of research and development, the company launched its TrueLimb product last month, describing it as an affordable, next-generation prosthetic arm using a custom remote-fitting process where the user never has to leave home.

The technologies used for TrueLimb’s customization and manufacturing are pretty impressive, in that they both cut costs and make the user’s experience a lot less stressful.

For starters, the entire purchase, sizing, and customization process for the prosthetic can be done remotely. Here’s how it works. First, prospective users fill out an eligibility form and give information about their residual limb. If they’re a qualified candidate for a prosthetic, Unlimited Tomorrow sends them a 3D scanner, which they use to scan their residual limb.

The company uses the scans to design a set of test sockets (the component that connects the residual limb to the prosthetic), which are mailed to the user. The company schedules a video meeting with the user for them to try on and discuss the different sockets, with the goal of finding the one that’s most comfortable; new sockets can be made based on the information collected during the video consultation. The user selects their skin tone from a swatch with 450 options, then Unlimited Tomorrow 3D prints and assembles the custom prosthetic and tests it before shipping it out.

“We print the socket, forearm, palm, and all the fingers out of durable nylon material in full color,” LaChappelle told Singularity Hub in an email. “The only components that aren’t 3D printed are the actuators, tendons, electronics, batteries, sensors, and the nuts and bolts. We are an extreme example of final use 3D printing.”

Unlimited Tomorrow’s website lists TrueLimb’s cost as “as low as $7,995.” When you consider the customization and capabilities of the prosthetic, this is incredibly low. According to LaChappelle, the company created a muscle sensor that picks up muscle movement at a higher resolution than the industry standard electromyography sensors. The sensors read signals from nerves in the residual limb used to control motions like fingers bending. This means that when a user thinks about bending a finger, the nerve fires and the prosthetic’s sensors can detect the signal and translate it into the action.

“Working with children using our device, I’ve witnessed a physical moment where the brain “clicks” and starts moving the hand rather than focusing on moving the muscles,” LaChappelle said.

The cost savings come both from the direct-to-consumer model and the fact that Unlimited Tomorrow doesn’t use any outside suppliers. “We create every piece of our product,” LaChappelle said. “We don’t rely on another prosthetic manufacturer to make expensive sensors or electronics. By going direct to consumer, we cut out all the middlemen that usually drive costs up.” Similar devices on the market can cost up to $100,000.

Unlimited Tomorrow is primarily focused on making prosthetics for kids; when they outgrow their first TrueLimb, they send it back, where the company upcycles the expensive quality components and integrates them into a new customized device.

Unlimited Tomorrow isn’t the first to use 3D printing for prosthetics. Florida-based Limbitless Solutions does so too, and industry experts believe the technology is the future of artificial limbs.

“I am constantly blown away by this tech,” LaChappelle said. “We look at technology as the means to augment the human body and empower people.”

Image Credit: Unlimited Tomorrow Continue reading

Posted in Human Robots

#436977 The Top 100 AI Startups Out There Now, ...

New drug therapies for a range of chronic diseases. Defenses against various cyber attacks. Technologies to make cities work smarter. Weather and wildfire forecasts that boost safety and reduce risk. And commercial efforts to monetize so-called deepfakes.

What do all these disparate efforts have in common? They’re some of the solutions that the world’s most promising artificial intelligence startups are pursuing.

Data research firm CB Insights released its much-anticipated fourth annual list of the top 100 AI startups earlier this month. The New York-based company has become one of the go-to sources for emerging technology trends, especially in the startup scene.

About 10 years ago, it developed its own algorithm to assess the health of private companies using publicly-available information and non-traditional signals (think social media sentiment, for example) thanks to more than $1 million in grants from the National Science Foundation.

It uses that algorithm-generated data from what it calls a company’s Mosaic score—pulling together information on market trends, money, and momentum—along with other details ranging from patent activity to the latest news analysis to identify the best of the best.

“Our final list of companies is a mix of startups at various stages of R&D and product commercialization,” said Deepashri Varadharajanis, a lead analyst at CB Insights, during a recent presentation on the most prominent trends among the 2020 AI 100 startups.

About 10 companies on the list are among the world’s most valuable AI startups. For instance, there’s San Francisco-based Faire, which has raised at least $266 million since it was founded just three years ago. The company offers a wholesale marketplace that uses machine learning to match local retailers with goods that are predicted to sell well in their specific location.

Image courtesy of CB Insights
Funding for AI in Healthcare
Another startup valued at more than $1 billion, referred to as a unicorn in venture capital speak, is Butterfly Network, a company on the East Coast that has figured out a way to turn a smartphone phone into an ultrasound machine. Backed by $350 million in private investments, Butterfly Network uses AI to power the platform’s diagnostics. A more modestly funded San Francisco startup called Eko is doing something similar for stethoscopes.

In fact, there are more than a dozen AI healthcare startups on this year’s AI 100 list, representing the most companies of any industry on the list. In total, investors poured about $4 billion into AI healthcare startups last year, according to CB Insights, out of a record $26.6 billion raised by all private AI companies in 2019. Since 2014, more than 4,300 AI startups in 80 countries have raised about $83 billion.

One of the most intensive areas remains drug discovery, where companies unleash algorithms to screen potential drug candidates at an unprecedented speed and breadth that was impossible just a few years ago. It has led to the discovery of a new antibiotic to fight superbugs. There’s even a chance AI could help fight the coronavirus pandemic.

There are several AI drug discovery startups among the AI 100: San Francisco-based Atomwise claims its deep convolutional neural network, AtomNet, screens more than 100 million compounds each day. Cyclica is an AI drug discovery company in Toronto that just announced it would apply its platform to identify and develop novel cannabinoid-inspired drugs for neuropsychiatric conditions such as bipolar disorder and anxiety.

And then there’s OWKIN out of New York City, a startup that uses a type of machine learning called federated learning. Backed by Google, the company’s AI platform helps train algorithms without sharing the necessary patient data required to provide the sort of valuable insights researchers need for designing new drugs or even selecting the right populations for clinical trials.

Keeping Cyber Networks Healthy
Privacy and data security are the focus of a number of AI cybersecurity startups, as hackers attempt to leverage artificial intelligence to launch sophisticated attacks while also trying to fool the AI-powered systems rapidly coming online.

“I think this is an interesting field because it’s a bit of a cat and mouse game,” noted Varadharajanis. “As your cyber defenses get smarter, your cyber attacks get even smarter, and so it’s a constant game of who’s going to match the other in terms of tech capabilities.”

Few AI cybersecurity startups match Silicon Valley-based SentinelOne in terms of private capital. The company has raised more than $400 million, with a valuation of $1.1 billion following a $200 million Series E earlier this year. The company’s platform automates what’s called endpoint security, referring to laptops, phones, and other devices at the “end” of a centralized network.

Fellow AI 100 cybersecurity companies include Blue Hexagon, which protects the “edge” of the network against malware, and Abnormal Security, which stops targeted email attacks, both out of San Francisco. Just down the coast in Los Angeles is Obsidian Security, a startup offering cybersecurity for cloud services.

Deepfakes Get a Friendly Makeover
Deepfakes of videos and other types of AI-manipulated media where faces or voices are synthesized in order to fool viewers or listeners has been a different type of ongoing cybersecurity risk. However, some firms are swapping malicious intent for benign marketing and entertainment purposes.

Now anyone can be a supermodel thanks to Superpersonal, a London-based AI startup that has figured out a way to seamlessly swap a user’s face onto a fashionista modeling the latest threads on the catwalk. The most obvious use case is for shoppers to see how they will look in a particular outfit before taking the plunge on a plunging neckline.

Another British company called Synthesia helps users create videos where a talking head will deliver a customized speech or even talk in a different language. The startup’s claim to fame was releasing a campaign video for the NGO Malaria Must Die showing soccer star David Becham speak in nine different languages.

There’s also a Seattle-based company, Wellsaid Labs, which uses AI to produce voice-over narration where users can choose from a library of digital voices with human pitch, emphasis, and intonation. Because every narrator sounds just a little bit smarter with a British accent.

AI Helps Make Smart Cities Smarter
Speaking of smarter: A handful of AI 100 startups are helping create the smart city of the future, where a digital web of sensors, devices, and cloud-based analytics ensure that nobody is ever stuck in traffic again or without an umbrella at the wrong time. At least that’s the dream.

A couple of them are directly connected to Google subsidiary Sidewalk Labs, which focuses on tech solutions to improve urban design. A company called Replica was spun out just last year. It’s sort of SimCity for urban planning. The San Francisco startup uses location data from mobile phones to understand how people behave and travel throughout a typical day in the city. Those insights can then help city governments, for example, make better decisions about infrastructure development.

Denver-area startup AMP Robotics gets into the nitty gritty details of recycling by training robots on how to recycle trash, since humans have largely failed to do the job. The U.S. Environmental Protection Agency estimates that only about 30 percent of waste is recycled.

Some people might complain that weather forecasters don’t even do that well when trying to predict the weather. An Israeli AI startup, ClimaCell, claims it can forecast rain block by block. While the company taps the usual satellite and ground-based sources to create weather models, it has developed algorithms to analyze how precipitation and other conditions affect signals in cellular networks. By analyzing changes in microwave signals between cellular towers, the platform can predict the type and intensity of the precipitation down to street level.

And those are just some of the highlights of what some of the world’s most promising AI startups are doing.

“You have companies optimizing mining operations, warehouse logistics, insurance, workflows, and even working on bringing AI solutions to designing printed circuit boards,” Varadharajanis said. “So a lot of creative ways in which companies are applying AI to solve different issues in different industries.”

Image Credit: Butterfly Network Continue reading

Posted in Human Robots

#436488 Tech’s Biggest Leaps From the Last 10 ...

As we enter our third decade in the 21st century, it seems appropriate to reflect on the ways technology developed and note the breakthroughs that were achieved in the last 10 years.

The 2010s saw IBM’s Watson win a game of Jeopardy, ushering in mainstream awareness of machine learning, along with DeepMind’s AlphaGO becoming the world’s Go champion. It was the decade that industrial tools like drones, 3D printers, genetic sequencing, and virtual reality (VR) all became consumer products. And it was a decade in which some alarming trends related to surveillance, targeted misinformation, and deepfakes came online.

For better or worse, the past decade was a breathtaking era in human history in which the idea of exponential growth in information technologies powered by computation became a mainstream concept.

As I did last year for 2018 only, I’ve asked a collection of experts across the Singularity University faculty to help frame the biggest breakthroughs and moments that gave shape to the past 10 years. I asked them what, in their opinion, was the most important breakthrough in their respective fields over the past decade.

My own answer to this question, focused in the space of augmented and virtual reality, would be the stunning announcement in March of 2014 that Facebook acquired Oculus VR for $2 billion. Although VR technology had been around for a while, it was at this precise moment that VR arrived as a consumer technology platform. Facebook, largely fueled by the singular interest of CEO Mark Zuckerberg, has funded the development of this industry, keeping alive the hope that consumer VR can become a sustainable business. In the meantime, VR has continued to grow in sophistication and usefulness, though it has yet to truly take off as a mainstream concept. That will hopefully be a development for the 2020s.

Below is a decade in review across the technology areas that are giving shape to our modern world, as described by the SU community of experts.

Digital Biology
Dr. Tiffany Vora | Faculty Director and Vice Chair, Digital Biology and Medicine, Singularity University

In my mind, this decade of astounding breakthroughs in the life sciences and medicine rests on the achievement of the $1,000 human genome in 2016. More-than-exponentially falling costs of DNA sequencing have driven advances in medicine, agriculture, ecology, genome editing, synthetic biology, the battle against climate change, and our fundamental understanding of life and its breathtaking connections. The “digital” revolution in DNA constituted an important model for harnessing other types of biological information, from personalized bio data to massive datasets spanning populations and species.

Crucially, by aggressively driving down the cost of such analyses, researchers and entrepreneurs democratized access to the source code of life—with attendant financial, cultural, and ethical consequences. Exciting, but take heed: Veritas Genetics spearheaded a $600 genome in 2019, only to have to shutter USA operations due to a money trail tangled with the trade war with China. Stay tuned through the early 2020s to see the pricing of DNA sequencing fall even further … and to experience the many ways that cheaper, faster harvesting of biological data will enrich your daily life.

Alex Gladstein | Chief Strategy Officer, Human Rights Foundation

The past decade has seen Bitcoin go from just an idea on an obscure online message board to a global financial network carrying more than 100 billion dollars in value. And we’re just getting started. One recent defining moment in the cryptocurrency space has been a stunning trend underway in Venezuela, where today, the daily dollar-denominated value of Bitcoin traded now far exceeds the daily dollar-denominated value traded on the Caracas Stock Exchange. It’s just one country, but it’s a significant country, and a paradigm shift.

Governments and corporations are following Bitcoin’s success too, and are looking to launch their own digital currencies. China will launch its “DC/EP” project in the coming months, and Facebook is trying to kickstart its Libra project. There are technical and regulatory uncertainties for both, but one thing is for certain: the era of digital currency has arrived.

Business Strategy and Entrepreneurship
Pascal Finnette | Chair, Entrepreneurship and Open Innovation, Singularity University

For me, without a doubt, the most interesting and quite possibly ground-shifting development in the fields of entrepreneurship and corporate innovation in the last ten years is the rapid maturing of customer-driven product development frameworks such as Lean Startup, and its subsequent adoption by corporates for their own innovation purposes.

Tools and frameworks like the Business Model Canvas, agile (software) development and the aforementioned Lean Startup methodology fundamentally shifted the way we think and go about building products, services, and companies, with many of these tools bursting onto the startup scene in the late 2000s and early 2010s.

As these tools matured they found mass adoption not only in startups around the world, but incumbent companies who eagerly adopted them to increase their own innovation velocity and success.

Ramez Naam | Co-Chair, Energy and Environment, Singularity University

The 2010s were the decade that saw clean electricity, energy storage, and electric vehicles break through price and performance barriers around the world. Solar, wind, batteries, and EVs started this decade as technologies that had to be subsidized. That was the first phase of their existence. Now they’re entering their third, most disruptive phase, where shifting to clean energy and mobility is cheaper than continuing to use existing coal, gas, or oil infrastructure.

Consider that at the start of 2010, there was no place on earth where building new solar or wind was cheaper than building new coal or gas power generation. By 2015, in some of the sunniest and windiest places on earth, solar and wind had entered their second phase, where they were cost-competitive for new power. And then, in 2018 and 2019, we started to see the edge of the third phase, as building new solar and wind, in some parts of the world, was cheaper than operating existing coal or gas power plants.

Food Technology
Liz Specht, Ph. D | Associate Director of Science & Technology, The Good Food Institute

The arrival of mainstream plant-based meat is easily the food tech advance of the decade. Meat analogs have, of course, been around forever. But only in the last decade have companies like Beyond Meat and Impossible Foods decided to cut animals out of the process and build no-compromise meat directly from plants.

Plant-based meat is already transforming the fast-food industry. For example, the introduction of the Impossible Whopper led Burger King to their most profitable quarter in many years. But the global food industry as a whole is shifting as well. Tyson, JBS, Nestle, Cargill, and many others are all embracing plant-based meat.

Augmented and Virtual Reality
Jody Medich | CEO, Superhuman-x

The breakthrough moment for augmented and virtual reality came in 2013 when Palmer Lucky took apart an Android smartphone and added optic lenses to make the first version of the Oculus Rift. Prior to that moment, we struggled with miniaturizing the components needed to develop low-latency head-worn devices. But thanks to the smartphone race started in 2006 with the iPhone, we finally had a suite of sensors, chips, displays, and computing power small enough to put on the head.

What will the next 10 years bring? Look for AR/VR to explode in a big way. We are right on the cusp of that tipping point when the tech is finally “good enough” for our linear expectations. Given all it can do today, we can’t even picture what’s possible. Just as today we can’t function without our phones, by 2029 we’ll feel lost without some AR/VR product. It will be the way we interact with computing, smart objects, and AI. Tim Cook, Apple CEO, predicts it will replace all of today’s computing devices. I can’t wait.

Philosophy of Technology
Alix Rübsaam | Faculty Fellow, Singularity University, Philosophy of Technology/Ethics of AI

The last decade has seen a significant shift in our general attitude towards the algorithms that we now know dictate much of our surroundings. Looking back at the beginning of the decade, it seems we were blissfully unaware of how the data we freely and willingly surrendered would feed the algorithms that would come to shape every aspect of our daily lives: the news we consume, the products we purchase, the opinions we hold, etc.

If I were to isolate a single publication that contributed greatly to the shift in public discourse on algorithms, it would have to be Cathy O’Neil’s Weapons of Math Destruction from 2016. It remains a comprehensive, readable, and highly informative insight into how algorithms dictate our finances, our jobs, where we go to school, or if we can get health insurance. Its publication represents a pivotal moment when the general public started to question whether we should be OK with outsourcing decision making to these opaque systems.

The ubiquity of ethical guidelines for AI and algorithms published just in the last year (perhaps most comprehensively by the AI Now Institute) fully demonstrates the shift in public opinion of this decade.

Data Science
Ola Kowalewski | Faculty Fellow, Singularity University, Data Innovation

In the last decade we entered the era of internet and smartphone ubiquity. The number of internet users doubled, with nearly 60 percent of the global population connected online and now over 35 percent of the globe owns a smartphone. With billions of people in a state of constant connectedness and therefore in a state of constant surveillance, the companies that have built the tech infrastructure and information pipelines have dominated the global economy. This shift from tech companies being the underdogs to arguably the world’s major powers sets the landscape we enter for the next decade.

Global Grand Challenges
Darlene Damm | Vice Chair, Faculty, Global Grand Challenges, Singularity University

The biggest breakthrough over the last decade in social impact and technology is that the social impact sector switched from seeing technology as something problematic to avoid, to one of the most effective ways to create social change. We now see people using exponential technologies to solve all sorts of social challenges in areas ranging from disaster response to hunger to shelter.

The world’s leading social organizations, such as UNICEF and the World Food Programme, have launched their own venture funds and accelerators, and the United Nations recently declared that digitization is revolutionizing global development.

Digital Biology
Raymond McCauley | Chair, Digital Biology, Singularity University, Co-Founder & Chief Architect, BioCurious; Principal, Exponential Biosciences

CRISPR is bringing about a revolution in genetic engineering. It’s obvious, and it’s huge. What may not be so obvious is the widespread adoption of genetic testing. And this may have an even longer-lasting effect. It’s used to test new babies, to solve medical mysteries, and to catch serial killers. Thanks to holiday ads from 23andMe and Ancestry.com, it’s everywhere. Testing your DNA is now a common over-the-counter product. People are using it to set their diet, to pick drugs, and even for dating (or at least picking healthy mates).

And we’re just in the early stages. Further down the line, doing large-scale studies on more people, with more data, will lead to the use of polygenic risk scores to help us rank our genetic potential for everything from getting cancer to being a genius. Can you imagine what it would be like for parents to pick new babies, GATTACA-style, to get the smartest kids? You don’t have to; it’s already happening.

Artificial Intelligence
Neil Jacobstein | Chair, Artificial Intelligence and Robotics, Singularity University

The convergence of exponentially improved computing power, the deep learning algorithm, and access to massive data resulted in a series of AI breakthroughs over the past decade. These included: vastly improved accuracy in identifying images, making self driving cars practical, beating several world champions in Go, and identifying gender, smoking status, and age from retinal fundus photographs.

Combined, these breakthroughs convinced researchers and investors that after 50+ years of research and development, AI was ready for prime-time applications. Now, virtually every field of human endeavor is being revolutionized by machine learning. We still have a long way to go to achieve human-level intelligence and beyond, but the pace of worldwide improvement is blistering.

Hod Lipson | Professor of Engineering and Data Science, Columbia University

The biggest moment in AI in the past decade (and in its entire history, in my humble opinion) was midnight, Pacific time, September 30, 2012: the moment when machines finally opened their eyes. It was the moment when deep learning took off, breaking stagnant decades of machine blindness, when AI couldn’t reliably tell apart even a cat from a dog. That seemingly trivial accomplishment—a task any one-year-old child can do—has had a ripple effect on AI applications from driverless cars to health diagnostics. And this is just the beginning of what is sure to be a Cambrian explosion of AI.

Divya Chander | Chair, Neuroscience, Singularity University

If the 2000s were the decade of brain mapping, then the 2010s were the decade of brain writing. Optogenetics, a technique for precisely mapping and controlling neurons and neural circuits using genetically-directed light, saw incredible growth in the 2010s.

Also in the last 10 years, neuromodulation, or the ability to rewire the brain using both invasive and non-invasive interfaces and energy, has exploded in use and form. For instance, the Braingate consortium showed us how electrode arrays implanted into the motor cortex could be used by paralyzed people to use their thoughts to direct a robotic arm. These technologies, alone or in combination with robotics, exoskeletons, and flexible, implantable, electronics also make possible a future of human augmentation.

Image Credit: Image by Jorge Guillen from Pixabay Continue reading

Posted in Human Robots

#436437 Why AI Will Be the Best Tool for ...

Dmitry Kaminskiy speaks as though he were trying to unload everything he knows about the science and economics of longevity—from senolytics research that seeks to stop aging cells from spewing inflammatory proteins and other molecules to the trillion-dollar life extension industry that he and his colleagues are trying to foster—in one sitting.

At the heart of the discussion with Singularity Hub is the idea that artificial intelligence will be the engine that drives breakthroughs in how we approach healthcare and healthy aging—a concept with little traction even just five years ago.

“At that time, it was considered too futuristic that artificial intelligence and data science … might be more accurate compared to any hypothesis of human doctors,” said Kaminskiy, co-founder and managing partner at Deep Knowledge Ventures, an investment firm that is betting big on AI and longevity.

How times have changed. Artificial intelligence in healthcare is attracting more investments and deals than just about any sector of the economy, according to data research firm CB Insights. In the most recent third quarter, AI healthcare startups raised nearly $1.6 billion, buoyed by a $550 million mega-round from London-based Babylon Health, which uses AI to collect data from patients, analyze the information, find comparable matches, then make recommendations.

Even without the big bump from Babylon Health, AI healthcare startups raised more than $1 billion last quarter, including two companies focused on longevity therapeutics: Juvenescence and Insilico Medicine.

The latter has risen to prominence for its novel use of reinforcement learning and general adversarial networks (GANs) to accelerate the drug discovery process. Insilico Medicine recently published a seminal paper that demonstrated how such an AI system could generate a drug candidate in just 46 days. Co-founder and CEO Alex Zhavoronkov said he believes there is no greater goal in healthcare today—or, really, any venture—than extending the healthy years of the human lifespan.

“I don’t think that there is anything more important than that,” he told Singularity Hub, explaining that an unhealthy society is detrimental to a healthy economy. “I think that it’s very, very important to extend healthy, productive lifespan just to fix the economy.”

An Aging Crisis
The surge of interest in longevity is coming at a time when life expectancy in the US is actually dropping, despite the fact that we spend more money on healthcare than any other nation.

A new paper in the Journal of the American Medical Association found that after six decades of gains, life expectancy for Americans has decreased since 2014, particularly among young and middle-aged adults. While some of the causes are societal, such as drug overdoses and suicide, others are health-related.

While average life expectancy in the US is 78, Kaminskiy noted that healthy life expectancy is about ten years less.

To Zhavoronkov’s point about the economy (a topic of great interest to Kaminskiy as well), the US spent $1.1 trillion on chronic diseases in 2016, according to a report from the Milken Institute, with diabetes, cardiovascular conditions, and Alzheimer’s among the most costly expenses to the healthcare system. When the indirect costs of lost economic productivity are included, the total price tag of chronic diseases in the US is $3.7 trillion, nearly 20 percent of GDP.

“So this is the major negative feedback on the national economy and creating a lot of negative social [and] financial issues,” Kaminskiy said.

Investing in Longevity
That has convinced Kaminskiy that an economy focused on extending healthy human lifespans—including the financial instruments and institutions required to support a long-lived population—is the best way forward.

He has co-authored a book on the topic with Margaretta Colangelo, another managing partner at Deep Knowledge Ventures, which has launched a specialized investment fund, Longevity.Capital, focused on the longevity industry. Kaminskiy estimates that there are now about 20 such investment funds dedicated to funding life extension companies.

In November at the inaugural AI for Longevity Summit in London, he and his collaborators also introduced the Longevity AI Consortium, an academic-industry initiative at King’s College London. Eventually, the research center will include an AI Longevity Accelerator program to serve as a bridge between startups and UK investors.

Deep Knowledge Ventures has committed about £7 million ($9 million) over the next three years to the accelerator program, as well as establishing similar consortiums in other regions of the world, according to Franco Cortese, a partner at Longevity.Capital and director of the Aging Analytics Agency, which has produced a series of reports on longevity.

A Cure for What Ages You
One of the most recent is an overview of Biomarkers for Longevity. A biomarker, in the case of longevity, is a measurable component of health that can indicate a disease state or a more general decline in health associated with aging. Examples range from something as simple as BMI as an indicator of obesity, which is associated with a number of chronic diseases, to sophisticated measurements of telomeres, the protective ends of chromosomes that shorten as we age.

While some researchers are working on moonshot therapies to reverse or slow aging—with a few even arguing we could expand human life on the order of centuries—Kaminskiy said he believes understanding biomarkers of aging could make more radical interventions unnecessary.

In this vision of healthcare, people would be able to monitor their health 24-7, with sensors attuned to various biomarkers that could indicate the onset of everything from the flu to diabetes. AI would be instrumental in not just ingesting the billions of data points required to develop such a system, but also what therapies, treatments, or micro-doses of a drug or supplement would be required to maintain homeostasis.

“Consider it like Tesla with many, many detectors, analyzing the behavior of the car in real time, and a cloud computing system monitoring those signals in real time with high frequency,” Kaminskiy explained. “So the same shall be applied for humans.”

And only sophisticated algorithms, Kaminskiy argued, can make longevity healthcare work on a mass scale but at the individual level. Precision medicine becomes preventive medicine. Healthcare truly becomes a system to support health rather than a way to fight disease.

Image Credit: Photo by h heyerlein on Unsplash Continue reading

Posted in Human Robots